SENS research: Difference between revisions
wikademia>Eme copied from wikipedia sens article |
Explain SENS repair strategies and compare aging research approaches |
||
| Line 1: | Line 1: | ||
'''SENS research''' investigates whether repairing damage that builds up with age can preserve or restore function in cells and tissues. SENS stands for '''[[Strategies for Engineered Negligible Senescence]]''', a framework proposed by Aubrey de Grey and colleagues. The idea is to identify kinds of damage, find ways to repair or compensate for each one, and test whether doing so improves health. Keeping damage below a harmful level through repeated repair is a goal of the framework.<ref>de Grey and colleagues (2002). [https://pubmed.ncbi.nlm.nih.gov/11976218/ Time to talk SENS: critiquing the immutability of human aging].</ref> | |||
* [[MitoSENS]] | |||
* [[LysoSENS]] | The SENS Research Foundation supported work on these ideas. In 2024 it merged with the Lifespan Extension Advocacy Foundation, also known as Lifespan.io, to form the Lifespan Research Institute.<ref>Lifespan Research Institute (2024). [https://lifespan.io/lifespan-io-and-sens-merge/ Lifespan.io and SENS Research Foundation announce their merger].</ref> | ||
* [[AmyloSENS]] | |||
* [[RepleniSENS]] | == Seven areas of SENS research == | ||
* [[ApoptoSENS]] | The seven areas group damage by the kind of repair that could address it. Each raises a different practical question.<ref>SENS Research Foundation (2022). [https://lifespan.io/wp-content/uploads/2025/06/SRF-RR-2022-1.4.pdf 2022 Research Report], pp. 25–26.</ref> | ||
* [[GlycoSENS]] - | |||
* '''[[Strategies for Engineered Negligible Senescence#Cancer-causing_nuclear_mutations/epimutations—OncoSENS|OncoSENS]]''' addresses cancer arising from mutations and changes in gene regulation in the cell nucleus. A proposed strategy focused on limiting the ability of cancer cells to keep dividing by maintaining their telomeres, the protective ends of chromosomes. | |||
* '''[[MitoSENS]]''' addresses mutations in mitochondrial DNA that can interfere with the cell's energy supply. One proposal is to compensate for the loss of proteins the mitochondria ordinarily make. | |||
* '''[[Strategies for Engineered Negligible Senescence#Intracellular_junk—LysoSENS|LysoSENS]]''' studies how to clear material that accumulates inside cells when their normal breakdown and recycling processes are insufficient. | |||
* '''[[Strategies for Engineered Negligible Senescence#Extracellular_junk—AmyloSENS|AmyloSENS]]''' studies how to clear protein deposits and other aggregates outside cells. | |||
* '''[[Strategies for Engineered Negligible Senescence#Cell_loss_and_atrophy—RepleniSENS|RepleniSENS]]''' addresses cell loss and the shrinking or weakening of tissues. Possible approaches include replacing lost cells or helping tissue regenerate. | |||
* '''[[Strategies for Engineered Negligible Senescence#Cell_senescence—ApoptoSENS|ApoptoSENS]]''' studies ways to remove harmful, persistent senescent cells. Cells can enter senescence in response to stress, stop dividing, and release signals that affect nearby cells. | |||
* '''[[Strategies for Engineered Negligible Senescence#Extracellular_crosslinks—GlycoSENS|GlycoSENS]]''' studies chemical crosslinks that build up between molecules outside cells and can make tissues less flexible. | |||
A finding in one area can help test the framework. For example, a 2016 mouse study found that removing certain cells marked by high p16 activity delayed several age-related problems and extended median lifespan. The study also found that removal during wound healing slowed closure, illustrating why the timing and choice of target can matter.<ref>Baker and colleagues (2016). [https://pubmed.ncbi.nlm.nih.gov/26840489/ Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan].</ref> | |||
== Other ways to study and intervene in aging == | |||
The ''hallmarks of aging'' framework describes interacting processes such as chronic inflammation, impaired cellular recycling, and stem cell exhaustion. Some hallmarks overlap with the SENS categories. The hallmark of impaired recycling, for example, can motivate efforts to improve how cells break down waste alongside efforts to remove specific deposits that have already accumulated.<ref>López-Otín and colleagues (2023). [https://pubmed.ncbi.nlm.nih.gov/36599349/ Hallmarks of aging: An expanding universe].</ref> | |||
Another approach tests whether changing how cells respond to nutrients can slow aspects of aging. Rapamycin affects a nutrient-sensing pathway and extended lifespan in a large mouse study.<ref>Harrison and colleagues (2009). [https://pubmed.ncbi.nlm.nih.gov/19587680/ Rapamycin fed late in life extends lifespan in genetically heterogeneous mice].</ref> In the CALERIE trial in adults, calorie restriction changed one DNA methylation measure of the pace of aging, while two other measures showed no clear change. The study measured biomarkers over two years. Survival and long-term health were separate questions.<ref>Waziry and colleagues (2023). [https://www.nature.com/articles/s43587-022-00357-y Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial].</ref> | |||
== David Sinclair and the information theory of aging == | |||
David Sinclair and colleagues propose that cells lose some of the information they use to regulate genes as they age. This ''epigenetic information'' includes chemical marks on DNA and features of how DNA is packaged. A cell can retain its DNA sequence while changes in gene regulation alter how well it carries out its usual work. | |||
In a 2023 study, Yang, Sinclair, and colleagues used an experimental mouse model to study what happens when DNA breaks are induced and repaired. They reported several aging-like changes and found that partial reprogramming reversed some measures.<ref>Yang and colleagues (2023). [https://pubmed.ncbi.nlm.nih.gov/36638792/ Loss of epigenetic information as a cause of mammalian aging].</ref> In earlier mouse work, Lu and colleagues reported improved visual function after partial reprogramming of retinal cells.<ref>Lu and colleagues (2020). [https://www.nature.com/articles/s41586-020-2975-4 Reprogramming to recover youthful epigenetic information and restore vision].</ref> A 2026 phase 1 trial began testing the safety and tolerability of an investigational epigenetic therapy for specific optic nerve conditions in people.<ref>[https://clinicaltrials.gov/study/NCT07290244 ClinicalTrials.gov record NCT07290244].</ref> How much loss of gene regulation contributes to natural aging across different tissues remains an open question. | |||
The two approaches could meet in a study of aging muscle. One question would be whether removing persistent senescent cells improves the ability of muscle to recover. Another would be whether restoring aspects of gene regulation in surviving cells helps. Comparing the approaches individually and together could show whether they address overlapping problems. Measures of muscle function would help researchers judge the significance of changes in molecular markers. | |||
== AI and Ray Kurzweil's forecasts == | |||
[[Artificial intelligence]] can help researchers decide what to test. In a 2023 study, Smer-Barreto and colleagues used machine learning to prioritize candidate senolytics, compounds intended to selectively eliminate senescent cells. Three candidates showed activity in laboratory tests on human cell lines. That gives ApoptoSENS-style research a way to narrow the search before experiments. Researchers would still need to test whether a candidate reaches the right tissue, spares useful cells, and improves tissue function.<ref>Smer-Barreto and colleagues (2023). [https://www.nature.com/articles/s41467-023-39120-1 Discovery of senolytics using machine learning].</ref> | |||
Futurist Ray Kurzweil has argued that AI could accelerate the development of therapies enough to reach ''longevity escape velocity''. In this scenario, advances would add more than one year to expected remaining life for every year that passes. It is a forecast about the pace of progress. Sinclair's hypothesis asks a different question about what changes inside aging cells. SENS gives researchers specific repair targets, and AI can help find candidates or compare measurements. Kurzweil's forecast also depends on whether such results translate into safe, durable treatments that people can access.<ref>Ray Kurzweil (2024). [https://www.penguinrandomhouse.com/books/535433/the-singularity-is-nearer-by-ray-kurzweil/9780593148914/ ''The Singularity Is Nearer''] and [https://www.youtube.com/watch?v=cipDXOhx9X4 a recorded talk on AI and longevity].</ref> | |||
==Discussion questions, essay ideas, and learning related AI prompt ideas== | |||
* If an intervention changes an epigenetic clock but leaves tissue function the same, what further evidence would help interpret the result? | |||
* Write an essay comparing the mouse senescent-cell clearance study and the CALERIE trial. Describe what each study measured and what would be needed to show more years of healthy life in people. | |||
* Give an AI tool the abstracts of the senolytic discovery and vision studies. Ask it to identify what was tested, what improved, and what remained uncertain. Check each answer against the population or model and the outcomes reported in the papers. | |||
==Readings from Wikipedia== | |||
* [[Wikipedia:Cellular senescence|Cellular senescence]] | |||
* [[Wikipedia:Epigenetic clock|Epigenetic clock]] | |||
* [[Wikipedia:Life extension|Life extension]] | |||
== See also == | |||
* [[Aging]] | |||
* [[Strategies for Engineered Negligible Senescence]] | |||
* [[Artificial intelligence]] | |||
== References == | |||
<references /> | |||
[[Category:Aging]] | |||
[[Category:Gerontology]] | |||
[[Category:Life extension]] | |||